Bill Barry, Ph.D.

Principal Statistical Research Scientist

Bill Barry, Ph.D.

Principal Statistical Research Scientist

William (Bill) Barry, PhD, is a biostatistician and Principal Research Scientist at Rho who has devoted his career to clinical research and efforts to efficiently and rigorously test novel therapeutics and innovative strategies to improve health outcomes in a variety of disease settings. Dr. Barry received a PhD in Biostatistics from the University of North Carolina in 2006, and has more than 12 years of experience in the design and conduct of phase I to III clinical trials. From 2007 to 2012, Dr. Barry was an Assistant Professor in the Department of Biostatistics and Bioinformatics at Duke University, and then from 2012 to 2018 at Dana-Farber Cancer Institute and Harvard Medical School in Boston, MA.  During his time on faculty at Duke and Harvard, he also served as a member of several national cooperative groups and research networks conducting multi-institutional trials in cancer. He joined Rho in 2018 as a Senior Research Scientist, and has been responsible for providing senior biostatistical leadership for NIH-funded data coordinating centers. In particular, he is a co-PI of the NIAID/DAIT-funded Statistical and Clinical Coordinating Center (SACCC) and a Scientific Leader of its Autoimmune Disease Group (ADG) focusing on the design and conduct of clinical trials under two consortia: Immune Tolerance Network (ITN) and Autoimmunity Centers of Excellence (ACE). He has also recently participated in the design and conduct of trials of medical and infectious diseases countermeasures under Biomedical and Advanced Research Development Authority (BARDA).

Dr. Barry has broad experience in the application of statistical methods for single- and multi-arm investigations into the safety and efficacy of drugs, biologics and vaccines, including adaptive designs, dose-finding studies, pharmacokinetic and pharmacodynamic studies, biomarker-driven studies, and translational research to discover and validate genomic and proteomic signatures. These research investigations have appeared in over 150 co-authored peer-reviewed publications.